Clive Meanwell is Executive Chair and Founder of Population Health Partners, a global investment firm based in New York, San Francisco, and London, focused on technologies which arrest the drivers of common and burdensome health conditions such as stroke and heart disease, diabetes, lung diseases, chronic pain, anxiety, and depression. He is also Vice Chairman of BB Biotech, the Swiss investor in biotechnology. Clive leads Metsera, a private company developing medicines for metabolic diseases.
Clive was the founder, Chief Executive and Chief Innovation Officer of The Medicines Company, acquired by Novartis in early 2020 for $9.7 billion. Prior to that, he was a Partner at the venture capital firm MPM Capital, and before then, he held senior global executive positions with the Roche group working out of Switzerland and the United States. He trained in medicine, with post-graduate specialization in cancer treatment, cancer research, clinical trials, statistics, and epidemiology. He holds M.B., Ch.B., and M.D. cum laude degrees from the University of Birmingham, UK.